Health Sector Sustainability and Transformation

Healthcare and life sciences leadership is more complex than ever. Public and private leaders are continuously grappling with new regulation, inflation, market consolidation, and other challenges.

Tapestry’s work with Fortune 100 directors and executives and heads of regulatory agencies gives us a deep understanding of the policy environment, capital markets, and long-term organizational transformation. Our initiatives include:

• The European Healthcare Innovation Leadership Network (EHILN): EHILN addressed unmet needs and patient treatment access in an era of severe budgetary pressure in Europe. The platform brought together leaders of multiple European healthcare organizations and industry to create and implement six multistakeholder drug development pilots. 
• Research initiatives: Alongside our standing networks and forums, Tapestry’s healthcare team conducts research to surface how senior leaders are interpreting and responding to critical developments in the sector. These often pave the way for more targeted forums to address identified challenges relating to sector sustainability and transformation.  Our latest research effort, “Advancing Sustainable Biopharmaceutical R&D in a Time of Uncertainty (May 2026),” describes Tapestry’s conversations from October 2025 to February 2026 with life sciences and health sector leaders about the shifting landscape for biopharmaceutical R&D. The resulting Summary of Themes synthesizes perspectives on US leadership and decision-making across HHS and FDA, evolving evidentiary expectations facing the sector, geopolitics and China, and new channels for stakeholder engagement.  These efforts draw on conversations with industry executives, board directors, regulatory and policy experts, and advocacy leaders, supplemented by insights from our Fortune 100 board director forums. [Read the Summary of Themes here.]